Anlon Healthcare Pvt Ltd. is gearing up for its initial public offering (IPO), which opens for subscription on August 26, 2025. The company, based in Rajkot, Gujarat, has been operational since 2013 and has made its mark in the pharmaceutical industry. Specializing in high-purity active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, Anlon Healthcare is positioning itself as a key player in the sector. With a promising product portfolio and an ambitious expansion plan, the company is looking to raise ₹121.03 crore through this IPO.
History around Anlon Healthcare’s journey
Founded in 2013, Anlon Healthcare began its manufacturing operations in 2017. It quickly carved a niche for itself in producing specialized pharmaceutical intermediates and APIs, including Loxoprofen sodium dihydrate, a widely used drug in pain management. The company is one of the few in India to manufacture this API, which is used in treating conditions like rheumatoid arthritis and lower back pain.
Anlon Healthcare’s approach includes custom manufacturing of complex chemical compounds, producing chemicals with purity levels beyond industry standards. The company has also been proactive in seeking approvals for its products from global regulators like Brazil, China, Japan, and the European Union.
Also read: SEBI Registered Investment Advisor
Objective of Anlon Healthcare going public
By going public, Anlon Healthcare aims to raise funds to expand its production capacity and support its research and development (R&D) activities. The proceeds from the IPO will be primarily used for:
- Capital expenditure (₹30.72 crore) to expand capacity.
- Repayment of borrowings (₹5 crore).
- Working capital requirements (₹43.15 crore).
- General corporate purposes.
The funds will also help Anlon Healthcare strengthen its market presence, particularly in the API and pharmaceutical intermediates segments, where it has a strong foothold.
You may also like: Best Stock Market Simulator Apps in India [2025]
Current status of the IPOcompany
As of the financial year 2025, Anlon Healthcare has posted impressive growth, particularly in its profit margins. The company has seen a rise in income from ₹66.69 crore in FY24 to ₹120.46 crore in FY25, alongside a significant increase in net profit. Anlon Healthcare’s focus on high-margin APIs, especially for niche products, has allowed it to achieve solid profitability despite setbacks in FY24 due to plant modifications for international certifications.
You may also like: Shreeji Shipping Global IPO Details
Anlon Healthcare IPOfinancials: Year-on-year performance
| Financial Year | Total Income (₹ Cr.) | Net Profit (₹ Cr.) | EPS (₹) | RoNW (%) |
| FY23 | ₹113.12 | ₹5.82 | ₹6.23 | 56.92 |
| FY24 | ₹66.69 | ₹9.66 | ₹6.23 | 56.92 |
| FY25 | ₹120.46 | ₹20.52 | ₹6.23 | 56.92 |
Anlon Healthcare IPOdetails: key information
| Detail | Information |
| IPO Open Date | August 26, 2025 |
| IPO Close Date | August 29, 2025 |
| Price Band | ₹86 – ₹91 per share |
| Issue Size | ₹121.03 Crore (Fresh issue) |
| Lot Size | 164 shares |
| Listing Date | September 3, 2025 |
| BSE & NSE Listing | Yes |
Anlon Healthcare IPO shareholding pattern
| Shareholder Category | % of Total Shares |
| Qualified Institutional Buyers (QIBs) | 75% |
| Non-Institutional Investors (NIIs) | 15% |
| Retail Investors | 10% |
Anlon Healthcare IPO fund utilization plan
Anlon Healthcare has outlined its plans for using the funds raised from the IPO:
- ₹30.72 crore for capital expenditure (expansion of manufacturing capacity).
- ₹5.00 crore for repayment of borrowings.
- ₹43.15 crore for working capital requirements.
- Remaining funds will be allocated for general corporate purposes.
Why should you invest in the IPO?
Advantages
- Strong Market Position: Anlon Healthcare manufactures key APIs, including Loxoprofen, which has significant demand in pain management.
- Expansion Plans: The company is set to expand its manufacturing capacity, potentially tripling its output, which will drive future revenue growth.
- Solid Financial Growth: The company has shown impressive profitability and significant growth in its net profit in FY25, positioning it well for long-term gains.
Disadvantages
- Aggressive Pricing: The IPO is priced at a P/E of 50 based on FY24 earnings, which may seem high for value investors.
- Regulatory Risks: Anlon Healthcare’s operations are subject to global regulatory approvals, which can impact its growth.
- Market Volatility: As with all IPOs, Anlon Healthcare is susceptible to market volatility, which could affect the stock’s post-listing performance.
Bottomline: Should you go for the Anlon Healthcare IPO?
The Anlon Healthcare IPO offers an interesting opportunity for investors who believe in the long-term growth potential of the Indian pharmaceutical industry. With a solid financial performance and an aggressive expansion plan, Anlon Healthcare seems poised for significant growth in the coming years. However, the high pricing of the IPO makes it more suitable for informed, long-term investors who can absorb some level of risk.
